Phathom Pharmaceuticals (PHAT) Notes Payables (2018 - 2019)
Phathom Pharmaceuticals' (PHAT) quarterly Notes Payables came in at $95.2 million in Q3 2019, up 4783.54% on a QoQ basis from $2.0 million in Q4 2018.
Phathom Pharmaceuticals (PHAT) Notes Payables (2018 - 2019) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 2 years of Notes Payables data on file, last reported at $95.2 million in Q3 2019.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $95.2 million in Q3 2019; TTM through Sep 2019 was $95.2 million, a N/A change from a year earlier, with the FY2018 full-year figure at $2.0 million, changed N/A from the prior year.
- Notes Payables for Q3 2019 stood at $95.2 million, up from $2.0 million in the prior quarter.
- Over the last five years, Notes Payables for PHAT reached as high as $95.2 million in Q3 2019 and fell as low as $2.0 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Phathom Pharmaceuticals | 945.22 Mn | 761.46 Mn | 46.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 95.23 Mn |
| Dec 31, 2018 | 1.95 Mn |